financetom
Business
financetom
/
Business
/
BMO on Fairfax Acquiring Sleep Country
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BMO on Fairfax Acquiring Sleep Country
Jul 23, 2024 10:02 AM

12:40 PM EDT, 07/23/2024 (MT Newswires) -- Fairfax's proposed acquisition of Sleep Country at $35 presents an attractive outcome for shareholders. The price more accurately reflects fair value and the implied valuation looks reasonable (~8.2x 2024E EV/EBITDA), writes BMO's Stephen MacLeod.

"We have for a long time appreciated Sleep Country's multi-year opportunity for growth and market share gains for everything "sleep." However, the near-term reality is that consumer spending remains choppy, and this offer provides shareholders with price certainty," MacLeod notes.

Revising target to match the $35 offer price. Rating lowered to Market Perform.

Price: 34.75, Change: +0.08, Percent Change: +0.23

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Thyssenkrupp starts due diligence phase on marine unit deal with Carlyle
Thyssenkrupp starts due diligence phase on marine unit deal with Carlyle
Mar 19, 2024
March 19 (Reuters) - Thyssenkrupp on Tuesday said it has entered a due diligence phase on the sale of its marine unit with investment firm Carlyle. At the same time, talks are being held with the German government on the state's participation in thyssenkrupp's marine business, the industrial conglomerate added. ...
AstraZeneca to buy Fusion Pharma for $2 billion in cash
AstraZeneca to buy Fusion Pharma for $2 billion in cash
Mar 19, 2024
March 19 (Reuters) - AstraZeneca ( AZN ) said on Tuesday it has agreed to buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc ( FUSN ) for about $2 billion in cash. The drugmaker will pay $21 per Fusion share plus a non-transferable contingent value right of $3 per share. ...
BRIEF-Fusion Pharmaceuticals To Be Acquired By Astrazeneca, Accelerating Development Of Next-Generation Radioconjugates To Treat Cancer
BRIEF-Fusion Pharmaceuticals To Be Acquired By Astrazeneca, Accelerating Development Of Next-Generation Radioconjugates To Treat Cancer
Mar 19, 2024
March 19 (Reuters) - Fusion Pharmaceuticals Inc ( FUSN ) : * FUSION PHARMACEUTICALS TO BE ACQUIRED BY ASTRAZENECA, ACCELERATING DEVELOPMENT OF NEXT-GENERATION RADIOCONJUGATES TO TREAT CANCER * REPRESENTING A TOTAL TRANSACTION VALUE OF APPROXIMATELY $2.4 BILLION INCLUDING CVR * SHAREHOLDERS TO RECEIVE $21.00 PER SHARE IN CASH AT CLOSING PLUS A NON-TRANSFERRABLE CVR OF $3.00 PER SHARE * UPFRONT...
JOYY Q4 Adjusted Earnings Rise, Revenue Declines; Issues Q1 Revenue Outlook
JOYY Q4 Adjusted Earnings Rise, Revenue Declines; Issues Q1 Revenue Outlook
Mar 19, 2024
03:15 AM EDT, 03/19/2024 (MT Newswires) -- JOYY ( YY ) reported Q4 adjusted earnings late Monday of $1.01 per diluted American depositary share, up from $0.65 per ADS a year earlier. Two analysts polled by Capital IQ expected $0.64. Revenue for the quarter ended Dec. 31 was $569.8 million, down from $604.9 million a year earlier. Four analysts surveyed...
Copyright 2023-2026 - www.financetom.com All Rights Reserved